Review Article| Volume 50, ISSUE 1, P91-107, February 2023

Combined Use of Magnetic Resonance Imaging and Biomarker Testing to Detect Clinically Significant Prostate Cancer


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Urologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Fuchs H.E.
        • et al.
        Cancer Statistics, 2021.
        CA Cancer J Clin. 2021; 71: 7-33
        • Rawla P.
        Epidemiology of Prostate Cancer.
        World J Oncol. 2019; 10: 63-89
        • Fitzmaurice C.
        • Abate D.
        • Abbasi N.
        • et al.
        Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.
        JAMA Oncol. 2019; 5: 1749-1768
        • Hugosson J.
        • Roobol M.J.
        • Mansson M.
        • et al.
        A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
        Eur Urol. 2019; 76: 43-51
        • Schroder F.H.
        • Hugosson J.
        • Roobol M.J.
        • et al.
        Prostate-cancer mortality at 11 years of follow-up.
        N Engl J Med. 2012; 366: 981-990
        • Schroder F.H.
        • Hugosson J.
        • Roobol M.J.
        • et al.
        Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.
        Lancet. 2014; 384: 2027-2035
        • Fenton J.J.
        • Weyrich M.S.
        • Durbin S.
        • et al.
        Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
        JAMA. 2018; 319: 1914-1931
        • Loeb S.
        • Bjurlin M.A.
        • Nicholson J.
        • et al.
        Overdiagnosis and overtreatment of prostate cancer.
        Eur Urol. 2014; 65: 1046-1055
        • Loeb S.
        • Vellekoop A.
        • Ahmed H.U.
        • et al.
        Systematic review of complications of prostate biopsy.
        Eur Urol. 2013; 64: 876-892
        • National Comprehensive Cancer Network
        Prostate Cancer Early Detection Guidelines.
        (Available at:) (Accessed July 22, 2022)
        • Drost F.H.
        • Osses D.F.
        • Nieboer D.
        • et al.
        Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.
        Cochrane Database Syst Rev. 2019; 4: CD012663
        • Bass E.J.
        • Pantovic A.
        • Connor M.J.
        • et al.
        Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis.
        Prostate Cancer Prostatic Dis. 2022; 25: 174-179
        • Sathianathen N.J.
        • Omer A.
        • Harriss E.
        • et al.
        Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.
        Eur Urol. 2020; 78: 402-414
        • Eyrich N.W.
        • Morgan T.M.
        • Tosoian J.J.
        Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions.
        Transl Androl Urol. 2021; 10: 3091-3103
        • McDonald M.L.
        • Parsons J.K.
        4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening.
        Urol Clin North Am. 2016; 43: 39-46
        • Stattin P.
        • Vickers A.J.
        • Sjoberg D.D.
        • et al.
        Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
        Eur Urol. 2015; 68: 207-213
        • Vickers A.
        • Vertosick E.A.
        • Sjoberg D.D.
        • et al.
        Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
        J Urol. 2018; 199: 1470-1474
        • Punnen S.
        • Nahar B.
        • Soodana-Prakash N.
        • et al.
        Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer.
        PLoS One. 2018; 13: e0201384
        • Parekh D.J.
        • Punnen S.
        • Sjoberg D.D.
        • et al.
        A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.
        Eur Urol. 2015; 68: 464-470
        • Ahmed H.U.
        • El-Shater Bosaily A.
        • Brown L.C.
        • et al.
        Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
        Lancet. 2017; 389: 815-822
        • Marzouk K.
        • Ehdaie B.
        • Vertosick E.
        • et al.
        Developing an effective strategy to improve the detection of significant prostate cancer by combining the 4Kscore and multiparametric MRI.
        Urol Oncol. 2019; 37: 672-677
        • Falagario U.G.
        • Martini A.
        • Wajswol E.
        • et al.
        Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.
        Eur Urol Oncol. 2020; 3: 700-704
        • de la Calle C.M.
        • Fasulo V.
        • Cowan J.E.
        • et al.
        Clinical Utility of 4Kscore((R)), ExosomeDx and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer.
        J Urol. 2021; 205: 452-460
        • McKiernan J.
        • Donovan M.J.
        • O'Neill V.
        • et al.
        A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
        JAMA Oncol. 2016; 2: 882-889
        • McKiernan J.
        • Donovan M.J.
        • Margolis E.
        • et al.
        A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
        Eur Urol. 2018; 74: 731-738
        • Falagario U.G.
        • Lantz A.
        • Jambor I.
        • et al.
        Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion.
        Int J Urol. 2021; 28: 47-52
        • de la Calle C.
        • Patil D.
        • Wei J.T.
        • et al.
        Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naive Men.
        J Urol. 2015; 194: 65-72
        • Nordstrom T.
        • Vickers A.
        • Assel M.
        • et al.
        Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
        Eur Urol. 2015; 68: 139-146
        • Seisen T.
        • Roupret M.
        • Brault D.
        • et al.
        Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy.
        Prostate. 2015; 75: 103-111
        • Chiu P.K.
        • Ng C.F.
        • Semjonow A.
        • et al.
        A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.
        Eur Urol. 2019; 75: 558-561
      1. United States Food and Drug Administration. 2022.
        (Available at:) (Accessed July 22, 2022)
        • Gnanapragasam V.J.
        • Burling K.
        • George A.
        • et al.
        The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population.
        Sci Rep. 2016; 6: 35364
        • Tosoian J.J.
        • Druskin S.C.
        • Andreas D.
        • et al.
        Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.
        Prostate Cancer Prostatic Dis. 2017; 20: 228-233
        • Carbunaru S.
        • Stinson J.
        • Babajide R.
        • et al.
        Performance of prostate health index and PSA density in a diverse biopsy-naive cohort with mpMRI for detecting significant prostate cancer.
        BJUI Compass. 2021; 2: 370-376
        • Fan Y.H.
        • Pan P.H.
        • Cheng W.M.
        • et al.
        The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer.
        Sci Rep. 2021; 11: 1286
        • Haese A.
        • Trooskens G.
        • Steyaert S.
        • et al.
        Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy.
        J Urol. 2019; 202: 256-263
        • Maggi M.
        • Del Giudice F.
        • Falagario U.G.
        • et al.
        SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study.
        Cancers (Basel). 2021; 13
        • Busetto G.M.
        • Del Giudice F.
        • Maggi M.
        • et al.
        Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy.
        World J Urol. 2021; 39: 1869-1877
        • Hendriks R.J.
        • van der Leest M.M.G.
        • Israel B.
        • et al.
        Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naive men.
        Prostate Cancer Prostatic Dis. 2021; 24: 1110-1119
        • Morote J.
        • Diaz F.
        • Celma A.
        • et al.
        Behavior of SelectMDx and Prostate-specific Antigen Density in the Challenging Scenario of Prostate Imaging-Reporting and Data System Category 3 Lesions.
        Eur Urol. 2022; 81: 124-125
        • Tomlins S.A.
        • Day J.R.
        • Lonigro R.J.
        • et al.
        Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
        Eur Urol. 2016; 70: 45-53
        • Tosoian J.J.
        • Trock B.J.
        • Morgan T.M.
        • et al.
        Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
        J Urol. 2021; 205: 732-739
        • Tosoian J.J.
        • Singhal U.
        • Davenport M.S.
        • et al.
        Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need.
        Urology. 2022; 164: 184-190
        • Vickers A.J.
        • Van Calster B.
        • Steyerberg E.W.
        Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests.
        BMJ. 2016; 352: i6
        • Schoots I.G.
        • Osses D.F.
        • Drost F.H.
        • et al.
        Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease.
        Transl Androl Urol. 2018; 7: 132-144
        • Filson C.P.
        • Natarajan S.
        • Margolis D.J.
        • et al.
        Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.
        Cancer. 2016; 122: 884-892
        • Pokorny M.R.
        • de Rooij M.
        • Duncan E.
        • et al.
        Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.
        Eur Urol. 2014; 66: 22-29
        • Venderink W.
        • van Luijtelaar A.
        • Bomers J.G.R.
        • et al.
        Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.
        Eur Urol. 2018; 73: 353-360
        • Schoots I.G.
        MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?.
        Transl Androl Urol. 2018; 7: 70-82
        • Stevens E.
        • Truong M.
        • Bullen J.A.
        • et al.
        Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer.
        Urol Oncol. 2020; 38: 846.e9-846.e16